Grace Lim1, Vladyslav Melnyk, Francesca L Facco, Jonathan H Waters, Kenneth J Smith. 1. From the Department of Anesthesiology (G.L., V.M., J.H.W.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Magee-Womens Research Institute and Foundation (F.L.F.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and the Department of Medicine and Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pennsylvania (K.J.S.).
Abstract
BACKGROUND: Cost-effectiveness analyses on cell salvage for cesarean delivery to inform national and societal guidelines on obstetric blood management are lacking. This study examined the cost-effectiveness of cell salvage strategies in obstetric hemorrhage from a societal perspective. METHODS: Markov decision analysis modeling compared the cost-effectiveness of three strategies: use of cell salvage for every cesarean delivery, cell salvage use for high-risk cases, and no cell salvage. A societal perspective and lifetime horizon was assumed for the base case of a 26-yr-old primiparous woman presenting for cesarean delivery. Each strategy integrated probabilities of hemorrhage, hysterectomy, transfusion reactions, emergency procedures, and cell salvage utilization; utilities for quality of life; and costs at the societal level. One-way and Monte Carlo probabilistic sensitivity analyses were performed. A threshold of $100,000 per quality-adjusted life-year gained was used as a cost-effectiveness criterion. RESULTS: Cell salvage use for cases at high risk for hemorrhage was cost-effective (incremental cost-effectiveness ratio, $34,881 per quality-adjusted life-year gained). Routine cell salvage use for all cesarean deliveries was not cost-effective, costing $415,488 per quality-adjusted life-year gained. Results were not sensitive to individual variation of other model parameters. The probabilistic sensitivity analysis showed that at the $100,000 per quality-adjusted life-year gained threshold, there is more than 85% likelihood that cell salvage use for cases at high risk for hemorrhage is favorable. CONCLUSIONS: The use of cell salvage for cases at high risk for obstetric hemorrhage is economically reasonable; routine cell salvage use for all cesarean deliveries is not. These findings can inform the development of public policies such as guidelines on management of obstetric hemorrhage.
BACKGROUND: Cost-effectiveness analyses on cell salvage for cesarean delivery to inform national and societal guidelines on obstetric blood management are lacking. This study examined the cost-effectiveness of cell salvage strategies in obstetric hemorrhage from a societal perspective. METHODS: Markov decision analysis modeling compared the cost-effectiveness of three strategies: use of cell salvage for every cesarean delivery, cell salvage use for high-risk cases, and no cell salvage. A societal perspective and lifetime horizon was assumed for the base case of a 26-yr-old primiparous woman presenting for cesarean delivery. Each strategy integrated probabilities of hemorrhage, hysterectomy, transfusion reactions, emergency procedures, and cell salvage utilization; utilities for quality of life; and costs at the societal level. One-way and Monte Carlo probabilistic sensitivity analyses were performed. A threshold of $100,000 per quality-adjusted life-year gained was used as a cost-effectiveness criterion. RESULTS: Cell salvage use for cases at high risk for hemorrhage was cost-effective (incremental cost-effectiveness ratio, $34,881 per quality-adjusted life-year gained). Routine cell salvage use for all cesarean deliveries was not cost-effective, costing $415,488 per quality-adjusted life-year gained. Results were not sensitive to individual variation of other model parameters. The probabilistic sensitivity analysis showed that at the $100,000 per quality-adjusted life-year gained threshold, there is more than 85% likelihood that cell salvage use for cases at high risk for hemorrhage is favorable. CONCLUSIONS: The use of cell salvage for cases at high risk for obstetric hemorrhage is economically reasonable; routine cell salvage use for all cesarean deliveries is not. These findings can inform the development of public policies such as guidelines on management of obstetric hemorrhage.
Authors: Patrick J Culligan; John A Myers; Roger P Goldberg; Linda Blackwell; Stephan F Gohmann; Troy D Abell Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2004-07-29
Authors: Corine M Koopmans; Karin van der Tuuk; Henk Groen; Johannes P R Doornbos; Irene M de Graaf; Pauline C M van der Salm; Martina M Porath; Simone M I Kuppens; Ella J Wijnen; Robert Aardenburg; Aren J van Loon; Bettina M C Akerboom; Peggy J A van der Lans; Ben W J Mol; Maria G van Pampus Journal: Acta Obstet Gynecol Scand Date: 2014-04 Impact factor: 3.636
Authors: Carol McLoughlin; Tracy E Roberts; Louise J Jackson; Philip Moore; Matthew Wilson; Richard Hooper; Shubha Allard; Ian Wrench; Lee Beresford; James Geoghegan; Jane Daniels; Sue Catling; Vicki A Clark; Paul Ayuk; Stephen Robson; Fang Gao-Smith; Matthew Hogg; Doris Lanz; Julie Dodds; Khalid S Khan Journal: BMJ Open Date: 2019-02-19 Impact factor: 2.692
Authors: Raja Bhaskara Rajasekaran; Antony J R Palmer; Duncan Whitwell; Thomas D A Cosker; David Pigott; Orosz Zsolt; Robert Booth; M R J P Gibbons; Andrew Carr Journal: J Bone Oncol Date: 2021-09-16 Impact factor: 4.072
Authors: Xiao Xu; Vrunda B Desai; Peter E Schwartz; Cary P Gross; Haiqun Lin; Maria J Schymura; Jason D Wright Journal: Womens Health Rep (New Rochelle) Date: 2022-03-28
Authors: Ruchika Goel; Molly R Petersen; Eshan U Patel; Zoe Packman; Evan M Bloch; Eric A Gehrie; Parvez M Lokhandwala; Paul M Ness; Beth Shaz; Louis M Katz; Steven M Frank; Aaron A R Tobian Journal: Transfusion Date: 2020-08-31 Impact factor: 3.157